-
1دورية أكاديمية
المؤلفون: Bost, JP, Ojansivu, M, Munson, MJ, Wesen, E, Gallud, A, Gupta, D, Gustafsson, O, Saher, O, Radler, J, Higgins, SG, Lehto, T, Holme, MN, Dahlen, A, Engkvist, O, Stromstedt, PE, Andersson, S, Smith, CIE, Stevens, MM, Esbjorner, EK, Collen, A, El Andaloussi, S
المصدر: Communications biology. 5(1):185
مصطلحات موضوعية: Medicin och hälsovetenskap
-
2دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
3دورية أكاديمية
المؤلفون: Ivanova A; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden., Badertscher L; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden., O'Driscoll G; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden.; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden., Bergman J; Medicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden., Gordon E; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden., Gunnarsson A; Structure and Biophysics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden., Johansson C; Clinical Pharmacology and Safety Sciences, Sweden Imaging Hub, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden., Munson MJ; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden., Spinelli C; Research Institute of the McGill University Health Centre, Glen Site, McGill University, Montreal, Quebec, H4A 3J1, Canada., Torstensson S; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden., Vilén L; DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden., Voirel A; Medicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden., Wiseman J; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden., Rak J; Research Institute of the McGill University Health Centre, Glen Site, McGill University, Montreal, Quebec, H4A 3J1, Canada., Dekker N; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden., Lázaro-Ibáñez E; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden.; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50, Sweden.
المصدر: Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2023 Dec; Vol. 10 (34), pp. e2304389. Date of Electronic Publication: 2023 Oct 22.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: WILEY-VCH Country of Publication: Germany NLM ID: 101664569 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2198-3844 (Electronic) Linking ISSN: 21983844 NLM ISO Abbreviation: Adv Sci (Weinh) Subsets: MEDLINE
مواضيع طبية MeSH: Extracellular Vesicles*/metabolism, Mice ; Animals ; Humans ; Ligands ; Proteins/metabolism ; Drug Delivery Systems ; Cell Communication
-
4دورية أكاديمية
المؤلفون: Kaur N; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., de la Ballina LR; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway., Haukaas HS; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Torgersen ML; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Radulovic M; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Munson MJ; Advanced Drug Delivery, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Sabirsh A; Advanced Drug Delivery, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Stenmark H; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Simonsen A; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway., Carlsson SR; Department of Medical Biochemistry and Biophysics, University of Umeå, Umeå, Sweden., Lystad AH; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
المصدر: The EMBO journal [EMBO J] 2023 Sep 04; Vol. 42 (17), pp. e113105. Date of Electronic Publication: 2023 Jul 06.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8208664 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1460-2075 (Electronic) Linking ISSN: 02614189 NLM ISO Abbreviation: EMBO J Subsets: MEDLINE
مواضيع طبية MeSH: Sphingomyelins* , Ubiquitins*, Humans ; Autophagy-Related Protein 5/metabolism ; Autophagy-Related Proteins/genetics ; Autophagy-Related Proteins/metabolism ; Autophagy ; Microtubule-Associated Proteins/metabolism ; Autophagy-Related Protein 12/metabolism ; Membrane Proteins/metabolism
-
5دورية أكاديمية
المؤلفون: Joubert F; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, UK., Munson MJ; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Sabirsh A; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden., England RM; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, UK. Electronic address: Richard.England@astrazeneca.com., Hemmerling M; Medicinal Chemistry, Early Respiratory & Immunology, R&D, AstraZeneca, Gothenburg, Sweden., Alexander C; School of Pharmacy, University of Nottingham, Nottingham, UK., Ashford MB; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, UK.
المصدر: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2023 Apr; Vol. 356, pp. 580-594. Date of Electronic Publication: 2023 Mar 17.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE
مواضيع طبية MeSH: Dendrimers*/chemistry, Polylysine ; Transfection ; Gene Transfer Techniques
-
6دورية أكاديمية
المؤلفون: Ng MYW; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, 0372, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, University of Oslo, 0450, Oslo, Norway., Charsou C; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, 0372, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, University of Oslo, 0450, Oslo, Norway., Lapao A; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, 0372, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, University of Oslo, 0450, Oslo, Norway., Singh S; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, 0372, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, University of Oslo, 0450, Oslo, Norway., Trachsel-Moncho L; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, 0372, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, University of Oslo, 0450, Oslo, Norway., Schultz SW; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, University of Oslo, 0450, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital Montebello, 0379, Oslo, Norway., Nakken S; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, University of Oslo, 0450, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Montebello, 0379, Oslo, Norway., Munson MJ; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, 0372, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, University of Oslo, 0450, Oslo, Norway.; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Simonsen A; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, 0372, Oslo, Norway. anne.simonsen@medisin.uio.no.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, University of Oslo, 0450, Oslo, Norway. anne.simonsen@medisin.uio.no.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital Montebello, 0379, Oslo, Norway. anne.simonsen@medisin.uio.no.
المصدر: Nature communications [Nat Commun] 2022 Oct 21; Vol. 13 (1), pp. 6283. Date of Electronic Publication: 2022 Oct 21.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
-
7دورية أكاديمية
المؤلفون: Munson MJ; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Advanced Drug Delivery, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Mathai BJ; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Ng MYW; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Trachsel-Moncho L; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., de la Ballina LR; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Simonsen A; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, The Norwegian Radium Hospital Montebello, Oslo, Norway.
المصدر: Autophagy [Autophagy] 2022 Feb; Vol. 18 (2), pp. 467-469. Date of Electronic Publication: 2022 Jan 09.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101265188 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1554-8635 (Electronic) Linking ISSN: 15548627 NLM ISO Abbreviation: Autophagy Subsets: MEDLINE
-
8دورية أكاديمية
المؤلفون: Munson MJ; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, N-0372, Oslo, Norway. michael.munson@astrazeneca.com.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0316, Oslo, Norway. michael.munson@astrazeneca.com.; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. michael.munson@astrazeneca.com., Mathai BJ; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, N-0372, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0316, Oslo, Norway., Ng MYW; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, N-0372, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0316, Oslo, Norway., Trachsel-Moncho L; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, N-0372, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0316, Oslo, Norway., de la Ballina LR; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, N-0372, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0316, Oslo, Norway., Schultz SW; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0316, Oslo, Norway.; Department of Molecular Cell Biology, The Norwegian Radium Hospital Montebello, N-0379, Oslo, Norway., Aman Y; Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478, Lørenskog, Norway., Lystad AH; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, N-0372, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0316, Oslo, Norway., Singh S; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, N-0372, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0316, Oslo, Norway., Singh S; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0316, Oslo, Norway.; Department of Tumor Biology, The Norwegian Radium Hospital Montebello, N-0379, Oslo, Norway., Wesche J; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0316, Oslo, Norway.; Department of Tumor Biology, The Norwegian Radium Hospital Montebello, N-0379, Oslo, Norway., Fang EF; Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478, Lørenskog, Norway., Simonsen A; Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, N-0372, Oslo, Norway. anne.simonsen@medisin.uio.no.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0316, Oslo, Norway. anne.simonsen@medisin.uio.no.; Department of Molecular Cell Biology, The Norwegian Radium Hospital Montebello, N-0379, Oslo, Norway. anne.simonsen@medisin.uio.no.
المصدر: Nature communications [Nat Commun] 2021 Oct 20; Vol. 12 (1), pp. 6101. Date of Electronic Publication: 2021 Oct 20.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
مواضيع طبية MeSH: Mitophagy*/drug effects, Intracellular Signaling Peptides and Proteins/*metabolism , Protein Kinase C-delta/*metabolism , Protein Serine-Threonine Kinases/*metabolism, Animals ; Autophagy ; Autophagy-Related Protein-1 Homolog/metabolism ; Autophagy-Related Proteins/metabolism ; Caenorhabditis elegans ; Cell Line, Tumor ; Deferiprone/pharmacology ; Fatty Acid-Binding Proteins/genetics ; Fatty Acid-Binding Proteins/metabolism ; Humans ; Intracellular Signaling Peptides and Proteins/antagonists & inhibitors ; Intracellular Signaling Peptides and Proteins/genetics ; Lysosomes/metabolism ; Mitochondria/metabolism ; Protein Kinase C-delta/antagonists & inhibitors ; Protein Kinase C-delta/genetics ; Protein Serine-Threonine Kinases/antagonists & inhibitors ; Protein Serine-Threonine Kinases/genetics ; Zebrafish
-
9دورية أكاديمية
المؤلفون: Munson MJ; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Michael.Munson@astrazeneca.com., O'Driscoll G; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Silva AM; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Lázaro-Ibáñez E; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Gallud A; Division of Chemical and Biomolecular Engineering, Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden., Wilson JT; Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, USA., Collén A; Projects, Research and Early Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Esbjörner EK; Division of Chemical and Biomolecular Engineering, Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden., Sabirsh A; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Alan.Sabirsh@astrazeneca.com.
المصدر: Communications biology [Commun Biol] 2021 Feb 16; Vol. 4 (1), pp. 211. Date of Electronic Publication: 2021 Feb 16.
نوع المنشور: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Nature Publishing Group UK Country of Publication: England NLM ID: 101719179 Publication Model: Electronic Cited Medium: Internet ISSN: 2399-3642 (Electronic) Linking ISSN: 23993642 NLM ISO Abbreviation: Commun Biol Subsets: MEDLINE
مواضيع طبية MeSH: Gene Transfer Techniques* , Nanoparticles* , RNA Transport*, Endosomes/*metabolism , Galectins/*metabolism , Lipids/*chemistry , RNA, Messenger/*metabolism, Galectins/genetics ; Genes, Reporter ; HeLa Cells ; Hep G2 Cells ; Humans ; Luminescent Proteins/genetics ; Luminescent Proteins/metabolism ; Microscopy, Fluorescence ; RNA, Messenger/genetics ; Recombinant Fusion Proteins/metabolism ; Time Factors ; Time-Lapse Imaging ; Red Fluorescent Protein
-
10دورية أكاديمية
المؤلفون: Ulkoski D; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston 02451, United States., Munson MJ; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Jacobson ME; Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37212, United States., Palmer CR; Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37212, United States., Carson CS; Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37240-0002, United States., Sabirsh A; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Wilson JT; Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37212, United States.; Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37240-0002, United States., Krishnamurthy VR; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston 02451, United States.
المصدر: ACS applied bio materials [ACS Appl Bio Mater] 2021 Feb 15; Vol. 4 (2), pp. 1640-1654. Date of Electronic Publication: 2021 Jan 19.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
بيانات الدورية: Publisher: ACS Publications Country of Publication: United States NLM ID: 101729147 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2576-6422 (Electronic) Linking ISSN: 25766422 NLM ISO Abbreviation: ACS Appl Bio Mater Subsets: MEDLINE
مواضيع طبية MeSH: Gene Transfer Techniques/*standards , Genetic Therapy/*methods , Polymers/*chemistry , RNA, Messenger/*metabolism